RACC’s Oak Hill Bio Merger Brings $175M in Funding to Advance Angelman Syndrome Therapy
Market Chameleon (Mon, 27-Jul 11:15 AM)
RACC and Oak Hill Bio Join Forces to Push Angelman Syndrome Therapy Toward Phase 3 Milestone
Market Chameleon (Mon, 27-Jul 8:57 AM)
